Management

Zoltan Kiss, Ph.D. - He founded Zoltan Kiss Fat Research company in 2017. The company is based on his extensive research, helped by various paid collaborations, showing that low doses of two human proteins, used either in highly purified or recombinant form, can greatly reduce excess visceral (abdominal) fat in appropriate obese animal models without significantly affecting general obesity. He also showed that one of them, when used at somewhat higher, commercially still viable, doses either orally or by a systemic method to treat obese mice can either prevent further weight gain or normalize body weight when mice are reverted to a standard (low fat) diet. The company hopes to find a partner for the development one of the proteins to treat both excess visceral fat and obesity as well as the numerous related disorders.

*About the Founder: Zoltan Kiss, Ph.D., had an extensive academic research career before founding and leading several biotechnological companies. Until 2004, he was Professor and Section Leader at the University of Minnesota. Prior to that, he was a Senior Investigator at the National Cancer Institute (4 years) and held several faculty positions in the U.S. and Europe. Dr. Kiss holds a Ph.D. degree, and his research so far has resulted in 114 peer-reviewed articles and 27 issued international patents as well as 5 filed patent applications on the treatments of cancer cachexia, wounds, and various metabolic disorders including specific treatment of excess visceral fat. Most recently, Dr. Kiss’s research has been focusing on (1) finding effective interventions to normalize excess visceral obesity and determining the nature of relationships between visceral fat and various metabolic disorders and tumor growth (like breast cancer) in appropriate mouse models using the ZKPr1 and ZKPr2 nontoxic human proteins, (2) using ZKPr1 to reduce obesity along with normalization of excess visceral fat, (3) searching for the primary mechanisms by which ZKPr1 prevents cancer cachexia (Zoltan Kiss CanCureLab), (4) searching for the mechanisms by which ZKPr1 extends life expectancy of old mice, and (5) the role of the effects of ZKPr1 on mesenchymal stem cells in its demonstrated positive effects on would healing.